Press Releases

Hogan Lovells is selected for Novartis Preferred Firm Program

Washington D.C.,13 February 2020 – Hogan Lovells is pleased to announce that it has been selected for the newly adopted Novartis Preferred Firm Panel 3.0. We have pledged to meet the...

Press Releases

Hogan Lovells represents Howard University in new hospital management services agreement with Adventist HealthCare

Washington D.C., 12 February 2020 – International law firm Hogan Lovells represented Howard University, which operates Howard University Hospital, in a management services agreement with...

Press Releases

Proliferation of new tech applications ramps up challenges to anti-bribery and corruption compliance, Hogan Lovells reports

London and Washington, D.C., 4 February 2020 – More than half of businesses say that technologies such as chat apps are making it harder to monitor bribery and corruption, according...

Press Releases

Brexit Day 31 January 2020

Commentary from Charles Brasted, Head of the Hogan Lovells Public Law & Policy Team in the UK

To paraphrase Douglas Adams, we all like deadlines; we like the whooshing sound they make...

Press Releases

Hogan Lovells calls for collaboration between policy makers and businesses to encourage innovation with new Privacy 2040 initiative

London and Washington, D.C., 28 January 2020 – Global law firm Hogan Lovells has today called for a new type of public dialogue on the opportunities and challenges arising from the...

Press Releases

Hogan Lovells Advises Achaogen in Bankruptcy Sale

Press Releases

Hogan Lovells comments on U.S. Treasury Department's new rules for CFIUS

Washington, 15 January 2020 - The U.S. Department of the Treasury this week issued final regulations to implement the Foreign Investment Risk Review Modernization Act, which expands the...

Press Releases

Hogan Lovells team advises Gilead Sciences in a license agreement with Xencor, Inc. for Use of XmAb® Antibody Technologies in investigational agents for HIV

New York, 14 January 2020 – International law firm Hogan Lovells has advised Gilead Sciences, Inc. in entering into a technology license agreement with Xencor, Inc., a clinical-stage...

Loading data